Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
R Rosell, E Carcereny, R Gervais… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
[PDF][PDF] Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan …
A Falcone, S Ricci, I Brunetti, E Pfanner… - Journal of clinical …, 2007 - researchgate.net
Purpose The Gruppo Oncologico Nord Ovest (GONO) conducted a phase III study
comparing fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI [irinotecan 165 …
comparing fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI [irinotecan 165 …
Quality of life as a primary end point in oncology
F Roila, E Cortesi - Annals of oncology, 2001 - Elsevier
Background In cancer clinical trials, the standard end points include response rates,
progression free and overall survival, toxicity. These evaluation criteria do not measure how …
progression free and overall survival, toxicity. These evaluation criteria do not measure how …
[HTML][HTML] Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi… - … England Journal of …, 2014 - Mass Medical Soc
Background A fluoropyrimidine plus irinotecan or oxaliplatin, combined with bevacizumab (a
monoclonal antibody against vascular endothelial growth factor), is standard first-line …
monoclonal antibody against vascular endothelial growth factor), is standard first-line …
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials
R Iacovelli, D Alesini, A Palazzo, P Trenta… - Cancer treatment …, 2014 - Elsevier
Antiangiogenic agents (AAs) have reported grater efficacy compared to interferon. Despite
these advances, radiological complete response to therapy is rare. We meta-analyzed the …
these advances, radiological complete response to therapy is rare. We meta-analyzed the …
Adjuvant chemotherapy in resected colon cancer: when, how and how long?
AJ Gelibter, S Caponnetto, F Urbano, A Emiliani… - Surgical Oncology, 2019 - Elsevier
The benefit of adjuvant chemotherapy has been clearly established in the adjuvant setting
for node-positive colon cancer. A number of trials in the adjuvant setting have analyzed the …
for node-positive colon cancer. A number of trials in the adjuvant setting have analyzed the …
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving …
P Maione, F Perrone, C Gallo, L Manzione… - Journal of Clinical …, 2005 - iris.unito.it
PURPOSE: To study the prognostic value for overall survival of baseline assessment of
functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non …
functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non …
[PDF][PDF] Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
A Sartore-Bianchi, M Moroni, S Veronese… - Journal of Clinical …, 2007 - publicationslist.org
Purpose In a previous cohort study, we proposed that responsiveness of metastatic
colorectal cancer (mCRC) to anti–epidermal growth factor receptor (EGFR) monoclonal …
colorectal cancer (mCRC) to anti–epidermal growth factor receptor (EGFR) monoclonal …
Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients
C Raimondi, A Gradilone, G Naso, B Vincenzi… - Breast cancer research …, 2011 - Springer
Currently used methods to detect and enumerate circulating tumor cells (CTCs) rely on the
expression of the epithelial cell adhesion molecule (EpCAM) and cytokeratins. This …
expression of the epithelial cell adhesion molecule (EpCAM) and cytokeratins. This …
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
G Masi, F Loupakis, L Salvatore, L Fornaro… - The lancet …, 2010 - thelancet.com
Background The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …
been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 …